Germline heterozygous pathogenic ATM variants are associated with fivefold higher risk of breast cancer by the age of 50 years [67] and some rare variants have been shown to have penetrance as high as the BRCA2 gene [69]. This evidence concerns the gene BRCA2 and breast carcinoma.